SAN DIEGO, CA - April 30, 2025 (NEWMEDIAWIRE) - Quantumzyme Corp. (OTC: QTZM), a biotechnology company leveraging computational enzyme engineering, today announced that it is in contact with OTC Markets Group regarding the placement of a “Caveat Emptor” designation on the Company’s securities.
Quantumzyme immediately made contact with OTC Markets and has opened a dialogue to understand and address the concerns leading to the designation. The Company is committed to working cooperatively and as swiftly as possible with OTC Markets to have the Caveat Emptor status removed. Quantumzyme has also retained legal counsel to support a prompt and effective resolution.
In addition, Quantumzyme unequivocally denies any affiliation, association, or involvement with an entity which reportedly distributed promotional SMS text messages mentioning the Company. Quantumzyme did not authorize, endorse, participate in, or have prior knowledge of these messages. The Company condemns any such unauthorized promotional activity and will fully cooperate with any regulatory review related to this matter.
“Quantumzyme takes regulatory compliance and market integrity with the utmost seriousness,” stated Naveen Kulkarni, CEO of Quantumzyme. “We will pursue all appropriate steps to protect the company’s reputation and ensure accurate, transparent communication with our shareholders and the market.”
The Company will provide further updates as appropriate and remains focused on executing its business strategy and delivering long-term value to shareholders.
For the most current information and updates, please visit our website at www.quantumzymecorp.com.
About Quantumzyme Corp.
Quantumzyme Corp. is a pioneering biotransformation company revolutionizing chemical processes through sustainable, enzyme-based solutions. Specializing in green chemistry, it harnesses quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to design high-performance biocatalysts that enhance efficiency, reduce waste, and minimize environmental impact. By integrating computational modeling with wet-lab validation, Quantumzyme delivers scalable, cost-effective biocatalysis solutions that improve industrial sustainability. Offering end-to-end enzyme development services - from discovery and engineering to process optimization and scale-up - Quantumzyme empowers its partners to adopt greener, more efficient production methods. Committed to sustainability and innovation, the company envisions a future where biotechnology drives global solutions for climate change, pollution, and resource efficiency, making eco-friendly biocatalysis the industry standard.
Disclaimer
The information contained in this press release is provided by Quantumzyme Corp. (“Quantumzyme”) for general informational purposes only. This release may include forward-looking statements that reflect Quantumzyme’s current expectations, estimates, projections, and assumptions about future events, business performance, market conditions, or technological developments. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Forward-looking statements are based on management’s beliefs and assumptions as of the date of this press release and are subject to change without notice.
Quantumzyme makes no representations or warranties, express or implied, regarding the accuracy, completeness, or reliability of the information contained herein. The company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future developments, or changes in expectations, except as required by applicable law. Past performance should not be taken as an indicator of future results, and readers should not place undue reliance on any projections or expectations presented in this release.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it provide financial, investment, or legal advice. Any references to market trends, scientific advancements, or industry insights are provided for contextual purposes only and should not be interpreted as endorsements, guarantees, or definitive predictions of future developments. Readers and investors are encouraged to conduct their own due diligence and seek independent professional advice before making any investment or business decisions related to Quantumzyme or its affiliates.
Media Contact:
Naveen Kulkarni
Chief Executive Officer
Quantumzyme Corp.
15656 Bernardo Center Drive, Suite 801
San Diego, CA 92127
Phone: +1 (858) 203-0312
Email: info@quantumzymecorp.com
Website: www.quantumzymecorp.com
View the original release on www.newmediawire.com
